Nanomedicine and macroscale materials in immuno-oncology

Qingxue Sun, Matthias Barz, Bruno G. De Geest, Mustafa Diken, Wim E. Hennink, Fabian Kiessling, Twan Lammers, Yang Shi

Research output: Contribution to journalReview articleAcademicpeer-review

15 Citations (Scopus)

Abstract

Immunotherapy is revolutionizing the treatment of cancer. It can achieve unprecedented responses in advanced-stage patients, including complete cures and long-term survival. However, immunotherapy also has limitations, such as its relatively low response rates and the development of severe side effects. These drawbacks are gradually being overcome by improving our understanding of the immune system, as well as by establishing combination regimens in which immunotherapy is combined with other treatment modalities. In addition to this, in recent years, progress made in chemistry, nanotechnology and materials science has started to impact immuno-oncology, resulting in more effective and less toxic immunotherapy interventions. In this context, multiple different nanomedicine formulations and macroscale materials have been shown to be able to boost anti-cancer immunity and the efficacy of immunomodulatory drugs. We here review nanotechnological and materials chemistry efforts related to endogenous and exogenous vaccination, to the engineering of antigen-presenting cells and T cells, and to the modulation of the tumor microenvironment. We also discuss limitations, current trends and future directions. Together, the insights provided and the evidence obtained indicate that there is a bright future ahead for engineering nanomedicines and macroscale materials for immuno-oncology applications.

Original languageEnglish
Pages (from-to)351-381
Number of pages31
JournalChemical Society reviews
Volume48
Issue number1
DOIs
Publication statusPublished - 7 Jan 2019

Fingerprint

Medical nanotechnology
Oncology
T-cells
Immune system
Poisons
Materials science
Nanotechnology
Tumors
Modulation
Pharmaceutical Preparations

Cite this

Sun, Q., Barz, M., De Geest, B. G., Diken, M., Hennink, W. E., Kiessling, F., ... Shi, Y. (2019). Nanomedicine and macroscale materials in immuno-oncology. Chemical Society reviews, 48(1), 351-381. https://doi.org/10.1039/c8cs00473k
Sun, Qingxue ; Barz, Matthias ; De Geest, Bruno G. ; Diken, Mustafa ; Hennink, Wim E. ; Kiessling, Fabian ; Lammers, Twan ; Shi, Yang. / Nanomedicine and macroscale materials in immuno-oncology. In: Chemical Society reviews. 2019 ; Vol. 48, No. 1. pp. 351-381.
@article{95a7df8cd5534582a5d9e9c20dc4283c,
title = "Nanomedicine and macroscale materials in immuno-oncology",
abstract = "Immunotherapy is revolutionizing the treatment of cancer. It can achieve unprecedented responses in advanced-stage patients, including complete cures and long-term survival. However, immunotherapy also has limitations, such as its relatively low response rates and the development of severe side effects. These drawbacks are gradually being overcome by improving our understanding of the immune system, as well as by establishing combination regimens in which immunotherapy is combined with other treatment modalities. In addition to this, in recent years, progress made in chemistry, nanotechnology and materials science has started to impact immuno-oncology, resulting in more effective and less toxic immunotherapy interventions. In this context, multiple different nanomedicine formulations and macroscale materials have been shown to be able to boost anti-cancer immunity and the efficacy of immunomodulatory drugs. We here review nanotechnological and materials chemistry efforts related to endogenous and exogenous vaccination, to the engineering of antigen-presenting cells and T cells, and to the modulation of the tumor microenvironment. We also discuss limitations, current trends and future directions. Together, the insights provided and the evidence obtained indicate that there is a bright future ahead for engineering nanomedicines and macroscale materials for immuno-oncology applications.",
author = "Qingxue Sun and Matthias Barz and {De Geest}, {Bruno G.} and Mustafa Diken and Hennink, {Wim E.} and Fabian Kiessling and Twan Lammers and Yang Shi",
year = "2019",
month = "1",
day = "7",
doi = "10.1039/c8cs00473k",
language = "English",
volume = "48",
pages = "351--381",
journal = "Chemical Society reviews",
issn = "0306-0012",
publisher = "Royal Society of Chemistry",
number = "1",

}

Sun, Q, Barz, M, De Geest, BG, Diken, M, Hennink, WE, Kiessling, F, Lammers, T & Shi, Y 2019, 'Nanomedicine and macroscale materials in immuno-oncology' Chemical Society reviews, vol. 48, no. 1, pp. 351-381. https://doi.org/10.1039/c8cs00473k

Nanomedicine and macroscale materials in immuno-oncology. / Sun, Qingxue; Barz, Matthias; De Geest, Bruno G.; Diken, Mustafa; Hennink, Wim E.; Kiessling, Fabian; Lammers, Twan; Shi, Yang.

In: Chemical Society reviews, Vol. 48, No. 1, 07.01.2019, p. 351-381.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - Nanomedicine and macroscale materials in immuno-oncology

AU - Sun, Qingxue

AU - Barz, Matthias

AU - De Geest, Bruno G.

AU - Diken, Mustafa

AU - Hennink, Wim E.

AU - Kiessling, Fabian

AU - Lammers, Twan

AU - Shi, Yang

PY - 2019/1/7

Y1 - 2019/1/7

N2 - Immunotherapy is revolutionizing the treatment of cancer. It can achieve unprecedented responses in advanced-stage patients, including complete cures and long-term survival. However, immunotherapy also has limitations, such as its relatively low response rates and the development of severe side effects. These drawbacks are gradually being overcome by improving our understanding of the immune system, as well as by establishing combination regimens in which immunotherapy is combined with other treatment modalities. In addition to this, in recent years, progress made in chemistry, nanotechnology and materials science has started to impact immuno-oncology, resulting in more effective and less toxic immunotherapy interventions. In this context, multiple different nanomedicine formulations and macroscale materials have been shown to be able to boost anti-cancer immunity and the efficacy of immunomodulatory drugs. We here review nanotechnological and materials chemistry efforts related to endogenous and exogenous vaccination, to the engineering of antigen-presenting cells and T cells, and to the modulation of the tumor microenvironment. We also discuss limitations, current trends and future directions. Together, the insights provided and the evidence obtained indicate that there is a bright future ahead for engineering nanomedicines and macroscale materials for immuno-oncology applications.

AB - Immunotherapy is revolutionizing the treatment of cancer. It can achieve unprecedented responses in advanced-stage patients, including complete cures and long-term survival. However, immunotherapy also has limitations, such as its relatively low response rates and the development of severe side effects. These drawbacks are gradually being overcome by improving our understanding of the immune system, as well as by establishing combination regimens in which immunotherapy is combined with other treatment modalities. In addition to this, in recent years, progress made in chemistry, nanotechnology and materials science has started to impact immuno-oncology, resulting in more effective and less toxic immunotherapy interventions. In this context, multiple different nanomedicine formulations and macroscale materials have been shown to be able to boost anti-cancer immunity and the efficacy of immunomodulatory drugs. We here review nanotechnological and materials chemistry efforts related to endogenous and exogenous vaccination, to the engineering of antigen-presenting cells and T cells, and to the modulation of the tumor microenvironment. We also discuss limitations, current trends and future directions. Together, the insights provided and the evidence obtained indicate that there is a bright future ahead for engineering nanomedicines and macroscale materials for immuno-oncology applications.

UR - http://www.scopus.com/inward/record.url?scp=85059232549&partnerID=8YFLogxK

U2 - 10.1039/c8cs00473k

DO - 10.1039/c8cs00473k

M3 - Review article

VL - 48

SP - 351

EP - 381

JO - Chemical Society reviews

JF - Chemical Society reviews

SN - 0306-0012

IS - 1

ER -

Sun Q, Barz M, De Geest BG, Diken M, Hennink WE, Kiessling F et al. Nanomedicine and macroscale materials in immuno-oncology. Chemical Society reviews. 2019 Jan 7;48(1):351-381. https://doi.org/10.1039/c8cs00473k